Investigation of Adverse Drug Events in Nails during Breast Cancer Chemotherapy

DOI IR IR NDL Digital Collections 13 References

Bibliographic Information

Other Title
  • 乳がん化学療法における爪に対する副作用の実態調査

Search this article

Abstract

Epirubicin-cyclophosphamide (EC) and fluorouracil-epirubicin-cyclophosphamide (FEC),2 epirubicin-based regimens,are often switched to docetaxel (DOC) in chemotherapy before and after breast surgery.As nail discoloration had been frequently observed during these breast cancer chemotherapy regimens,we investigated adverse drug events in nails.Drug adverse events were observed in the nails of 87% of patients treated with EC,in 83% treated with FEC,and 58% treated with DOC following the switch from EC or FEC.With regard to the time of onset,most nail discoloration appeared after second or third course of chemotherapy with EC or FEC.Adverse drug events differed depending on the chemotherapy regimen.Nail discoloration was nearly all specific to EC and FEC and nail bed pain,onycholysis,and koilonychias tended to occur with DOC.Though most adverse drug events in the nails were mild,any of Grade 2 (CTCAE v 3.0) occurring would have impaired quality of life and caused psychological stress.Therefore,pharmacists should inform patients receiving these chemotherapies of the possibility of adverse drug events in the nails and observe them carefully.They should also recommend consultation with a dermatologist as early as possible if Grade 2 adverse drug events should occur.

Journal

References(13)*help

See more

Keywords

Details

Report a problem

Back to top